Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
16.04.2024 13:22:39
|
Johnson & Johnson Updates FY24 Earnings, Sales Outlook - Update
(RTTNews) - Drug major Johnson & Johnson (JNJ), while reporting a profit in its first quarter, compared to prior year's loss, on higher revenues, on Tuesday increased the midpoint for fiscal 2024 guidance for adjusted operational earnings per share and operational sales growth view. Meanwhile, it trimmed the midpoint of operational sales forecast in figures.
In pre-market activity on the NYSE, JNJ shares were losing around 1.8 percent to trade at $145.01.
For fiscal 2024, the company now expects adjusted earnings per share of $10.57 to $10.72, with a midpoint of $10.65. This represents a year-over-year growth of 6.6 percent to 8.1 percent.
The company previously expected adjusted earnings per share of $10.55 to $10.75, with a midpoint of $10.65, a growth of 6.4 percent to 8.4 percent.
Adjusted operational earnings per share is now expected to be $10.60 to $10.75, with a midpoint of $10.68. This represents a year-over-year growth of 6.9 percent to 8.4 percent.
The company's previous estimate was for earnings per share of $10.55 to $10.75, with a midpoint of $10.65, a growth of 6.4 percent to 8.4 percent.
For the year, sales are now projected to be $88 billion to $88.4 billion, compared to previously expected $87.8 billion to $88.6 billion, while mid point remains at $88.2 billion. The revised outlook represents a growth of 4.7 percent to 5.2 percent.
Operational sales are now projected to be $88.7 billion to $89.1 billion, with a mid point of $88 billion. This is compared to previously expected $88.2 billion to $89 billion, with a mid point at $88.6 billion. The revised outlook represents a growth of 5.5 percent to 6 percent, up from previously expected growth of 5 percent to 6 percent.
Adjusted operational sales growth is now expected to be 5.5 percent to 6.0 percent, compared to previously expected growth of 5.0 percent to 6.0 percent.
In fiscal 2023, adjusted income per share was $9.92 on sales of $85.159 billion.
Analysts on average expect the company to report earnings of $10.65 per share on sales of $88.43 billion for the year, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
In the first quarter, earnings were $5.35 billion, compared to loss of $491 million in the same period last year. Earnings per share were $2.20, compared to last year's loss of $0.19.
Adjusted earnings were $6.58 billion or $2.71 per share for the period, compared to $6.34 billion or $2.41 per share last year, while analysts projected $2.64 per share.
Revenue for the quarter grew 2.3 percent to $21.38 billion from $20.89 billion in the same period last year. Operational sales increased 3.9 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
26.09.25 |
Optimismus in New York: Dow Jones zum Ende des Freitagshandels mit Zuschlägen (finanzen.at) | |
25.09.25 |
Handel in New York: Dow Jones beendet den Handel mit Verlusten (finanzen.at) | |
25.09.25 |
Dow Jones aktuell: Dow Jones gibt zum Start des Donnerstagshandels nach (finanzen.at) | |
24.09.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte eine Investition in Johnson Johnson von vor einem Jahr abgeworfen (finanzen.at) | |
23.09.25 |
Dow Jones-Handel aktuell: Dow Jones sackt zum Ende des Dienstagshandels ab (finanzen.at) | |
23.09.25 |
Verluste in New York: Dow Jones präsentiert sich am Nachmittag schwächer (finanzen.at) | |
23.09.25 |
Dow Jones-Handel aktuell: Dow Jones am Dienstagmittag im Aufwind (finanzen.at) | |
19.09.25 |
Pluszeichen in New York: Anleger lassen Dow Jones zum Handelsende steigen (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 153,40 | 0,92% |
|